LABU240920P138000
- 0.60
- -3.90-86.67%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
10 Health Care Stocks With Whale Alerts In Today's Session
28 Top Rated U.S. Growth Stocks Month-to-date in Anticipation of Fed Cuts
What the Options Market Tells Us About Viking Therapeutics
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Natera Shares Are Trading Higher After the Company Announced the Publication of Three Peer-reviewed Papers, Resulting in Over 85 Peer-reviewed Publications on Its Cancer Diagnostic Test Signatera
Exas Science Shares Are Trading Higher After the Company Announced Data for Its Blood-based Colorectal Cancer Screening Test.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Piper Sandler Reiterates Overweight on Natera, Maintains $150 Price Target
Natera Analyst Ratings
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences